Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 10:11:20543581241235526.
doi: 10.1177/20543581241235526. eCollection 2024.

Royal Jelly, A Super Food, Protects Against Celecoxib-Induced Renal Toxicity in Adult Male Albino Rats

Hesham A M I Khalifa  1 , Naglaa Z H Eleiwa  1 , Heba A Nazim  1   2
Affiliations

Royal Jelly, A Super Food, Protects Against Celecoxib-Induced Renal Toxicity in Adult Male Albino Rats

Hesham A M I Khalifa et al. Can J Kidney Health Dis. .

Abstract
in English, French

Background: Celecoxib is a COX-2 nonsteroidal anti-inflammatory drug (NSAID). It is widely used for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Objective: This study aimed to explore the effect of long-term administration of celecoxib on kidney of male albino rats, and to study the potential effect of treatment discontinuation on such tissues. The study also examined the alleged ameliorative effect of royal jelly (RJ).

Methods: Fifty, male albino rats were divided into 5 equal groups; 10 each. Group 1: rats received no drug (control group). Group 2: rats received celecoxib (50 mg/kg/day, orally for 30 successive days). Group 3: rats received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days. Group 4: rats received celecoxib for 30 successive days, then rats were left untreated for another 30 days. Group 5: rats received celecoxib and RJ for 30 successive days, then rats were left untreated for another 30 days.

Results: Long-term celecoxib administration caused significant elevation in kidney function tests, with ameliorative effects of RJ against celecoxib-induced renal toxicity.

Conclusion: Long-term celecoxib administration caused renal toxicity in male albino rats, with ameliorative effects of RJ.

Contexte: Le célécoxib est un anti-inflammatoire non stéroïdien (AINS) inhibiteur de COX-2. Ce médicament est largement utilisé pour le traitement symptomatique de l’arthrose, de la polyarthrite rhumatoïde et de la spondylarthrite ankylosante.

Objectifs: Cet essai visait à examiner l’effet d’une administration à long terme de célécoxib sur les reins de rats albinos mâles, à étudier les possibles effets de l’arrêt du traitement sur ces tissus et à vérifier l’effet d’amélioration allégué de la gelée royale.

Méthodologie: Cinquante rats albinos mâles ont été répartis en cinq groupes égaux (10 rats par groupe). Groupe 1 (groupe témoin): rats n’ayant reçu aucun médicament. Groupe 2: rats ayant reçu du célécoxib (50 mg/kg/jour, par voie orale pendant 30 jours consécutifs). Groupe 3: rats ayant reçu du célécoxib (50 mg/kg/jour, par voie orale) et de la gelée royale (300 mg/kg/jour, par voie orale) pendant 30 jours consécutifs. Groupe 4: rats ayant reçu du célécoxib pendant 30 jours consécutifs, puis laissés sans traitement pendant 30 jours supplémentaires. Groupe 5: rats ayant reçu du célécoxib et de la gelée royale pendant 30 jours consécutifs, puis laissés sans traitement pendant 30 jours supplémentaires.

Résultats: L’administration à long terme de célécoxib a entraîné une augmentation significative des tests de la fonction rénale; la gelée royale a montré des effets d’amélioration contre la toxicité rénale induite par le célécoxib.

Conclusion: L’administration à long terme de célécoxib a provoqué une toxicité rénale chez les rats albinos mâles contre laquelle la gelée royale a montré des effets protecteurs.

Keywords: celecoxib; kidney; renal; royal jelly; toxicity.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Effects of celecoxib (50 mg/kg/day, orally), royal jelly (300 mg/kg/day, orally), and treatments discontinuation on kidney profile in male albino rats. A: BUN (mg/dL), B: creatinine (mg/dL). Data are expressed as mean ± SD, n = 10/group. Group 1 received no drug (control). Group 2 received celecoxib (50 mg/kg/day, orally), for 30 successive days. Group 3 received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days. Group 4 received celecoxib (50 mg/kg/day, orally) for 30 successive days, then rats were left untreated for another 30 days. Group 5 received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days, then rats were left untreated for another 30 days.
Figure 2.
Figure 2.
Effects of celecoxib (50 mg/kg/day, orally), royal jelly (300 mg/kg/day, orally), and treatments discontinuation on serum oxidative status profile in male albino rats, A: MDA (nmol/mL), B: SOD (U/mL). Data are expressed as mean ± SD, n = 10/group. Group 1 received no drug (control). Group 2 received celecoxib (50 mg/kg/day, orally), for 30 successive days. Group 3 received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days. Group 4 received celecoxib (50 mg/kg/day, orally) for 30 successive days, then rats were left untreated for another 30 days. Group 5 received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days, then rats were left untreated for another 30 days.
Figure 3.
Figure 3.
Effects of celecoxib (50 mg/kg/day, orally), royal jelly (300 mg/kg/day, orally), and treatments discontinuation on A: renal Bax (%), B: renal Bcl-2 (%). Data are expressed as mean ± SD, n = 10/group. Group 1 received no drug (control). Group 2 received celecoxib (50 mg/kg/day, orally), for 30 successive days. Group 3 received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days. Group 4 received celecoxib (50 mg/kg/day, orally) for 30 successive days, then rats were left untreated for another 30 days. Group 5 received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days, then rats were left untreated for another 30 days.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Park SB, Jee BC, Kim SH, Cho YJ, Han M. Cyclooxygenase-2 inhibitor, celecoxib, inhibits leiomyoma cell proliferation through the nuclear factor κB pathway. Reprod Sci. 2014;21(9):1187-1195. - PMC - PubMed
    1. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000;59(4):957-980. - PubMed
    1. McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011;71:2457-2489. - PubMed
    1. Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res. 2011;10(4):655-683. - PMC - PubMed
    1. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000;7(3):159-175. - PubMed